Seres Therapeutics

General Information
Business:

We are a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics. The human microbiome is an ecology of microorganisms, including bacteria, fungi and viruses, that, when unhealthy, or dysbiotic, can leave the body more susceptible to infections, metabolic disorders, allergies, autoimmune disease, inflammation and other conditions. Our drugs are designed to restore health by repairing the function of a dysbiotic microbiome. We are initially focused on implementing our microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome, one of the most diverse microbiomes in the human body.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 44
Founded: 2010
Contact Information
Address 215 First Street, Cambridge, MA 02142, US
Phone Number (617) 945-9626
Web Address http://www.serestherapeutics.com
View Prospectus: Seres Therapeutics
Financial Information
Market Cap $681.0mil
Revenues $0.0 mil (last 12 months)
Net Income $-24.0 mil (last 12 months)
IPO Profile
Symbol MCRB
Exchange NASDAQ
Shares (millions): 7.4
Price range $18.00 - $18.00
Est. $ Volume $133.8 mil
Manager / Joint Managers Goldman Sachs/ BofA Merrill Lynch
CO-Managers Leerink Partners/ Canaccord Genuity
Expected To Trade: 6/26/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change